Back to Agenda
Session 5: Leveraging Artificial Intelligence (AI) In Clinical Trials - Opportunities and Ethical Considerations
Session Chair(s)
Florian Lasch
Biostatistics Specialist, Data Analytics and Methods Task Force, European Medicines Agency, Netherlands
Gunilla Andrew-Nielsen
Head of Clinical Trials, Swedish Medical Products Agency (läkemedelsverket), Sweden
The recent advancements in artificial intelligence have ignited a surge of hope regarding its groundbreaking potential, while simultaneously raising concerns about the societal consequences it may bring.
This session explores the opportunities of artificial intelligence (AI) in medicines development and health care. As a counterpoint, the session delves into the ethical considerations surrounding AI-driven healthcare around fairness, privacy, and transparency. The panel discussion brings both perspectives together to explore harnessing the potential of AI in medicines development in an ethical way.
Speaker(s)
A Vision for AI Driven Health Care
Antonio Estrella
Managing Director, Author, & Strategic Futurist,, Taliossa, Singapore
Unlocking the Potential of AI in Medicines Development
Nicole Mahoney, PhD
Executive Director US Regulatory Policy & Intelligence , EMD Serono, United States
Ensuring Ethical AI: Implications for Medicines Development
Arnaub Chatterjee, MHA, MPA
President & GM - Life Sciences, Datavant, United States
Diversity in Clinical Trials
Karen Hicks, MD, FACC
Deputy Director, Office of Medical Policy, CDER, FDA, United States
Standing Together
Xiaoxuan Liu
Senior Clinician Scientist in AI and Digital Health Technologies and an , Ophthalmology Doctor, University of Birmingham, United Kingdom
Have an account?